… lung cancer patient outcomes leading to curable lung cancer among early-stage diagnoses
and a chronic and manageable disease for patients with advanced and metastatic disease. …

… Of these criteria, the case for screening for lung cancer is fulfilled in some of the criteria: the
disease has serious consequences, treatment exists, and treatment is not too risky or toxic. …

… rapid disease progression with poor understanding of the mechanisms contributing to
therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent …

… Although clinical progress in SCLC treatment has been notoriously slow, a better understanding
of the biology of disease has uncovered novel vulnerabilities that might be amenable to …

… clinical progression of disease occurred in 13% of patients at only 4 weeks. Clinical progression
rates at … associated with more rapid disease progression (Table 3). Stage III patients with …

… lung cancer who had staging PET-CT scans before any therapy, and adequate follow-up (complete
to time of progression … We determined the relationship between times to progression (…

To determine whether in the natural history of metastatic non-small cell lung cancer (NSCLC)
a time interval exists when metastases are limited in number and/or destination organs. …

The incidence and mortality of small-cell lung cancer worldwide make this disease a notable
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …

… of lung cancer with smoking usually results in lung cancer … of pulmonary symptoms in lung
cancer patients and the treatment … [10] Some lung cancer patients have lung damage from …

… In conclusion, cancer and fibrosis are both severe lung diseases, and they share biological
pathways. Although the specific genetic and cellular mechanisms are not yet fully understood…